Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QLGN 
Qualigen Therapeutics Inc (QLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: QLGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.44% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.08M USD | Price to earnings Ratio 0.4 | 1Y Target Price 5 |
Price to earnings Ratio 0.4 | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.28 | 52 Weeks Range 1.61 - 6.48 | Updated Date 11/10/2025 |
52 Weeks Range 1.61 - 6.48 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -171.67% | Return on Equity (TTM) -841.66% |
Valuation
Trailing PE 0.4 | Forward PE - | Enterprise Value 15553769 | Price to Sales(TTM) 0.39 |
Enterprise Value 15553769 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA -0.05 | Shares Outstanding 2033072 | Shares Floating 1695450 |
Shares Outstanding 2033072 | Shares Floating 1695450 | ||
Percent Insiders 1.79 | Percent Institutions 0.12 |
Upturn AI SWOT
Qualigen Therapeutics Inc
Company Overview
History and Background
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel therapeutics to treat cancer and infectious diseases. Founded in 1996 as Signal Gene, the company initially focused on DNA-based diagnostics before shifting its focus to therapeutics.
Core Business Areas
- Oncology Therapeutics: Developing small molecule therapeutics targeting various cancers, including QN-247, a G-quadruplex selective transcription inhibitor.
- Infectious Disease Therapeutics: Developing diagnostics and therapeutics for infectious diseases like SARS-CoV-2 and other viral infections.
Leadership and Structure
Michael Poirier is the current Chairman, CEO, and President. The company operates with a management team overseeing research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- QN-247: A small molecule G-quadruplex selective transcription inhibitor being developed as a potential treatment for various cancers. Currently, QN-247 is in preclinical development. Competitors in cancer therapeutics include major pharmaceutical companies like Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb (BMY).
- FastPack SARS-CoV-2 IgG Serology Test: An antibody test used to detect SARS-CoV-2 antibodies. Qualigen previously sold it, but is not actively pushing it with the current market conditions. Roche (RHHBY) and Abbott (ABT) are major competitors in the serology testing market.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high innovation, intense competition, and stringent regulatory requirements. Cancer therapeutics and infectious disease diagnostics are significant growth areas.
Positioning
Qualigen is a small biotech company focusing on niche therapeutic areas. Its competitive advantage lies in its specific targeting mechanisms and innovative diagnostic tools.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is estimated to be in the hundreds of billions of dollars. The serology market is very saturated. Qualigen targets unmet needs within this market.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with unique mechanisms of action
- Experienced management team
- Potential for breakthrough therapies
- Proprietary technology platforms
Weaknesses
- Limited financial resources
- Reliance on preclinical data
- Limited market presence
- High dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancement of drug candidates through clinical trials
- Expansion into new therapeutic areas
- Regulatory approvals and market launch
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Funding limitations
Competitors and Market Share
Key Competitors
- PFE
- MRK
- BMY
- RHHBY
- ABT
Competitive Landscape
Qualigen faces significant competition from larger, well-established pharmaceutical companies. Its success hinges on the unique characteristics of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to its early-stage development status.
Future Projections: Future growth depends on successful clinical trials and commercialization of its drug candidates. Analyst estimates vary.
Recent Initiatives: Focus on advancing QN-247 and exploring new therapeutic applications.
Summary
Qualigen Therapeutics is a small biotechnology company with innovative drug candidates in early-stage development. The company's success heavily relies on positive clinical trial outcomes and securing partnerships. The company's limited financial resources and dependence on future events presents a high risk profile, but potential reward with its technologies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Qualigen Therapeutics Inc. (QLGN) SEC Filings
- Company Website
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is approximate and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qualigen Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2015-06-24 | Co-CEO, Chief Accounting Officer & Chairman of the Board Mr. Kevin A. Richardson II | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://qlgntx.com |
Full time employees - | Website https://qlgntx.com | ||
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.